VIDEO: Real-world faricimab data consistent with clinical trials
NEW YORK — In this presentation from OSN New York Retina, Ferhina S. Ali, MD, MPH, discusses how real-world experience with new anti-VEGF therapies is measuring up to what was seen in clinical trials.
She said real-world outcomes are generally poorer than outcomes in clinical trials. However, recent real-world data for faricimab has confirmed its efficacy and safety.
“We’ll await longer-term data to look at really that annualized injection burden and long-term treatment outcomes in the real world,” she said. “Also, we’ll await real-world data from the use of aflibercept [8 mg] out in the community.”
Collapse
Ali FS. Next generation anti-VEGFs: Is real world data consistent with the clinical trials? Presented at: OSN New York and OSN New York Retina; Nov. 8-10, 2024; New York.